Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a ...

Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

The incidence of non-Hodgkin’s lymphoma (NHL) is increasing among ... characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients ...

Primary central nervous system lymphoma (PCNSL) is a rare disease that is managed differently from other primary brain tumors and other types of systemic lymphomas. The use of high-dose ...